Next, we analyzed whether the association between CDK12 overexpression and sensitivity to MTX vs. resistance to standard chemotherapy, observed in our model systems in vitro and in vivo, was relevant to real-life breast cancer patients. The gene discussed is CDK12; the disease is breast carcinoma.